secwatch / observer
8-K filed December 6, 2023, 6:59 PM ET ticker IBIO CIK 0001420720
other material confidence high sentiment neutral materiality 0.50

iBio prices $4.5M public offering of common stock and warrants at $2.00/unit

iBio, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

iBio, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC valued at 5.5% of the gross proceeds (effective 2023-12-05).

Action
entry
Agreement
underwriting
Counterparty
A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC
Value
5.5% of the gross proceeds
Effective
2023-12-05
Exact text from the filing
On December 5, 2023, the Company entered into a placement agency agreement (the “ Placement Agency Agreement ”) with A.G.P./Alliance Global Partners (“ A.G.P. ”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“ Brookline ”), as co-placement agent (A.G.P. and Brookline are referred to herein, collectively, as the “ Placement Agents ”), pursuant to which the Placement Agents agreed to serve as the placement agents for the Company on a “reasonable efforts basis” for the issuance and sale of the Shares and Warrants.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

iBio, Inc. entered into Purchase Agreement with certain purchaser (the "Purchasers") valued at approximately $3.6 million (effective 2023-12-05).

Action
entry
Agreement
equity purchase
Counterparty
certain purchaser (the "Purchasers")
Value
approximately $3.6 million
Effective
2023-12-05
Exact text from the filing
On December 5, 2023, iBio, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement with certain purchaser (the “ Purchasers ”) identified on the signature pages thereto (the “ Purchase Agreement ”), pursuant to which the Company agreed to issue and sell, in a public offering (the “ Offering ”), (i) 600,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (ii) 1,650,000 pre-funded warrants
View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

iBio, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-23-123841
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.